| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | gossypol | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | spautin-1 | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |